Kuros Biosciences Ltd. · SIX:KURN
Kuros Biosciences — Investor Presentation (January 2024)
17 slides from Kuros Biosciences's investor presentation, January 2024
Slide 1: Kuros Biosciences: The future of spinal fusions
Kuros Biosciences The future of spinal fusions January 2024 1
Slide 2: Disclaimer
Disclaimer This presentation is private and confidential, has been furnished to you solely for your information and may not be reproduced, redistributed or disclosed in any way, in whole or in part, directly or indirectly, in or into the United States or the United Kingdom, Canada, Australia, Japan,
Slide 3: Kuros mission to ease the burden of spine-related pain
Kuros is on a mission to ease the burden of spine-related pain through developing superior orthobiologics 3
Slide 4: The future of spinal fusions
Addressing the fast-growing, multi-billion dollar global spinal fusion market Commercializing innovative, scientifically differentiated MagnetOs biologic fusion technology platform Pursuing platform expansion opportunities for MagnetOs with product development, clinical, and regulatory efforts Achie
Slide 5: Large, growing addressable spinal fusion market
Large, growing addressable spinal fusion market Value of global bone graft market1 ($M) US spinal procedures3 $3,070 $2,440 CAGR: 6% $1,382 $1,018 $918 $697 $725 $770 2022 2030 2,783,883 Value of US bone graft market2 ($M) $1,956 $1,555 1,748,606 $774 $585 $720 $535 $435 $462 2022 2030 2022 2030 ■ O
Slide 6: Spinal fusion surgery: challenges and opportunities
Spinal fusion surgery: challenges and opportunities 5.8% 17% 10% Cost CAGR 42% /QALY Failure rate for current surgical Re-operation rate for spine fusions is This is bad news for patients, payors, Spinal fusion surgeries conducted and medical organizations – where worldwide are growing treatment is
Slide 7: The MagnetOs technology has significant expansion opportunities
The MagnetOs technology has significant expansion opportunities Newly Expanded Market Opportunity ~$2.4 Billion Recent Developments: Focus on Magnetos, Discontinue Fibrin-PTH Posterolateral fusion • MAXA trial results show MagnetOs outperformed autograft, even in a difficult-to-treat patient populat
Slide 8: MagnetOs: A bone graft like no other
MagnetOs: A bone graft like no other MagnetOs is a bone graft like no other: thanks to its NeedleGrip ™ surface technology, it grows bone even in soft tissues.* This surface technology provides traction for our body’s vitally important ‘pro-healing’ immune cells (M2 macrophages).†‡1,2 This in turn,
Slide 9: MagnetOs: Platform overview
MagnetOs: Platform overview MagnetOs Granules, the portfolio foundation, proven to outperform autograft 1 Technology Product Attributes Regulatory Clearances (US)* Ready-to-Use Easy to Mold NeedleGrip Surface Free of Human Strip, Designed for Posterior Lumbar Pelvis & Formulation (Room Temperature D
Slide 10: MagnetOs: Overview of clinical studies
MagnetOs: Overview of clinical studies Prospective clinical studies building compelling repository of Level 1 clinical data Study Study design Initiated Fully enrolled Primary / Secondary Endpoint Investigator-led, posterolateral fusion 91 patients, MagnetOs Announced MAXA Granules vs autograft. CT
Slide 11: MAXA trial results: MagnetOs outperformed autograft
MAXA trial results: MagnetOs outperformed autograft MagnetOs showed: MAXA Trial Overview 73% higher fusion rate • Compared MagnetOs Granules (standalone) to autograft (at least 50% 1 bone harvested from the iliac crest) for posterolateral fusion relative to autograft in the challenging posterolatera
Slide 12: Rapid MagnetOs adoption has driven segment profitability
Rapid MagnetOs adoption has driven segment profitability Ordering Accounts Ordering MDs MagnetOs Revenue (USD M) 200 +32% $13.8 +74% +88% 200 CAGR 150 150 $8.1 100 $6.1 100 $5.1 $3.9 $2.9 50 50 $1.4 0 0 4Q 22 1H 23 4Q 22 1H 23 H1 20 H2 20 H1 21 H2 21 H1 22 H2 22 H1 23 MagnetOs Segment EBITDA (USD M)
Slide 13: Kuros' strategy for growth
Kuros’ strategy for growth 01 04 Lead with Science Increase Focus on Contracts Continue commitment to developing Level 1 clinical Increased focus on IDN and National agreements data through investigator-led studies will drive incremental revenue 05 Grow + Care 02 Increase Feet on the Street Increase
Slide 14: Delivering continuing strong financial performance
Delivering continuing strong financial performance Rapid Growth Driven by Commercial and 3Q 2023 Interim Results1 Clinical Execution YTD YoY Growth Medical Device Sales MagnetOs Revenue (USD M) $13.8 +152% (first nine months of 2023) $8.1 MagnetOs Segment EBITDA $6.1 + USD 4.1 M $5.1 (first nine mon
Slide 15: Management overview
Management overview Executive management Chris Fair Joost de Bruijn Chief Executive Officer Executive Director and President of Innovation and Strategy Daniel Geiger Sjoerd Musters Chief Financial Officer Chief Operating Officer Extended leadership team John Griffin Philippe Saudan Katherine Sage Ch
Slide 16: Strategic advisory board
Strategic advisory board Advisors Andrew A. Sama, MD Alpesh A. Patel, MD Kornelis Poelstra, MD, PhD Co-Chief of HSS Spine, NY Director of Orthopedic Rothman Orthopaedics. Spine Surgery, President, The Natl. Robotic Northwestern, Chicago Spine Institute of Las Vegas Thomas Cha, MD R. Todd Allen, MD F
Slide 17: The future of spinal fusions
Addressing the fast-growing, multi-billion dollar global spinal fusion market Commercializing innovative, scientifically differentiated MagnetOs biologic fusion technology platform Pursuing platform expansion opportunities for MagnetOs with product development, clinical, and regulatory efforts Achie
Kuros Biosciences — Investor Presentation (January 2024) on 6ix